Age: 0.7
Sex: M
Vaccine: HEP, HIBV, DTAP, FLUX, HEP, HIBV, IPV, MMR
Symptoms: Speech disorder, Stereotypy
Clinical narrative: Information has been received regarding a case in litigation concerning a 24 month old male who was injected with vaccines reportedly containing Thimerosal. It is alleged that between 12 and 25 micrograms of toxic ethylmercury were injected into the patient's body with each individual dose of Thimerosal and that the schedule of injections introduced a cumulative dose of 238 micrograms. It is further alleged that beginning approximately 13-NOV-1998, the patient began to display symptoms of neurological damage consistent with mercury poisoning, not limited to losing his language skills engaging in repetitive and stereotypical behaviors, suffering from diminished cognitive ability and becoming socially withdrawn. The patient has since been diagnosed as suffering with mercury poisoning and disintegrative (or late onset, degenerative or regressive) autism including severe, devastating and permanent neurological injuries. Follow up information has been received alleging that the patient was exposed to airborne vapors and mercury through the food chain, other mercury-laden products and power plant emissions. The patient was exposed to mercury from continually inhaling and ingesting industrial mercury emissions from fossil fuel driven power plants. The mercury included in the thimerosal-laden products and power plant emissions together caused the patient to suffer serious and permanent injuries, including mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments. It is further alleged that the patient had a heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. Additional follow up information indicated that the patient's family history is positive for allergic rhinitis and asthma. On 14-NOV-1996, 10-DEC-1996, and 13-AUG-1997 (Lot # 622792/E), the patient was vaccinated with the first, second, and third doses of hepatitis B vaccine. Other therapy included: globulin, immune (RHOGAM), DTP on 02-FEB-1997 (Lot 433-566), 19-MAR-1997 (444-251), 14-MAY-1997 (lot 444-259), 26-MAY-1998 (lot 453-844), and 14-SEP-2001 (lot 513A2); ACTHIB on 05-FEB-1997 (lot 433-566), 19-MAR-1997 (lot M035PE), 14-MAY-1997 (lot M30CPN), and 10-MAR-1998 (lot M285RJ); IPOL on 05-FEB-1997, 19-MAR-1997, 14-MAY-1997, and 14-SEP-2001; MMR II (lot 497814) on 19-NOV-1997; VARIVAX (lot 623130/0568E); and FLUSHIELD on 19-NOV-1997 (lot 497814) and 13-NOV-1998 (lot 20308). The first diagnosis of autism was noted to be July 1999. The patient was also noted to have neurodevelopment disorder. The autism and neurodevelopmental disorder was noted to be caused by thimerosal. Information received from medical records on 29-MAR-2007 contained the following adverse events: severe peanut allergy (2001), tree nut allergy; allergic rhinitis; mild persistent asthma; ear drainage (16-JUN-2000); recurrent ongoing otitis media (approximately January 1999); shellfish, strawberry, and grape jelly allergy. Upon internal review, autism, neurological injuries, serious and permanent injuries and mercury poisoning were considered to be other medical events. Additional information has been requested. All medical records are available upon request.